LC-1310

LC-1310 (6 days) potently inhibits human cytomegalovirus replication in primary human foreskin fibroblasts with an EC₅₀ of 0.3 μM, exhibits low cellular toxicity with a CC₅₀ of 12 μM, and has a therapeutic index of 40^[1].
LC-1310 reduces the expression of both HCMV IE1 and HCMV IE2 proteins in primary human foreskin fibroblasts starting 2 days post-viral inoculation and continuing through day 5^[1].
LC-1310 (0.01-1 μM; 6 days) combined with Ganciclovir (HY-13637) produces a synergistic inhibitory effect on human cytomegalovirus replication in primary human foreskin fibroblasts, with no significant associated cellular toxicity^[1].
LC-1310 (0.01-1 μM; 6 days) combined with Letermovir (HY-15233) produces an additive inhibitory effect on human cytomegalovirus replication in primary human foreskin fibroblasts, with no significant associated cellular toxicity^[1].
LC-1310 (0.1-0.5 μM; 1-5 days) did not show detectable antiviral activity against influenza A virus (A/WS/33) and human coronavirus OC43 in Huh7 human hepatocellular carcinoma cells in Madin-Darby canine kidney cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.